Randomized trial demonstrates superior visual acuity with ranibizumab over verteporfin in macular degeneration, highlighting its therapeutic efficacy.
Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
No takes yet. Share an insight, caveat, or question.
Brown et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: